UNIVERSITY OF MIAMI

Their core work

The University of Miami is a major US research university that contributes specialist biomedical and clinical research expertise to European health consortia. Their H2020 portfolio reveals two distinct research strengths: translational regenerative medicine — specifically iPSC-based approaches to spinal disc repair — and clinical implementation science focused on humanizing neonatal intensive care through family-integrated models. They join EU-led projects as a non-European partner, bringing American clinical research infrastructure and academic capacity that European consortia cannot source domestically. Their participation spans both bench-to-bedside biomedical research and health systems improvement, indicating a broad health faculty engaged in international collaboration.

What they specialise in

How they've shifted over time

UM's earliest H2020 engagement (iPSpine, starting 2019) was firmly in translational biomedical research — iPSC technology, biomaterials, and cellular therapies for structural tissue repair. Their second project (RISEinFAMILY, starting 2021) represents a sharp pivot toward clinical and behavioral health: family psychology in intensive care, nursing practice, humanization of care environments, and implementation equity. This shift likely reflects two separate research groups at the university rather than a single evolving team, but the net effect is a broader portfolio covering both upstream biomedical science and downstream clinical deployment.

UM appears to be expanding from laboratory-based regenerative medicine into implementation-focused clinical research, suggesting growing interest in health systems outcomes and equity — areas where future EU health calls are increasingly concentrated.

How they like to work

UM has not led any H2020 projects, joining exclusively as a participant or third-party expert within large European-led consortia. Their two projects collectively involve 36 partners across 13 countries, indicating they operate comfortably in complex multi-partner environments. This profile suggests they are sought out for specific domain expertise — stem cell biology or neonatal care research — rather than for project management or coordination capacity.

UM has built connections with 36 consortium partners spread across 13 countries through just two projects — a high partner-to-project ratio that reflects the large international consortia common in RIA and MSCA-RISE schemes. Their network is European-dominated in structure but anchored by UM's transatlantic position as the US node.

What sets them apart

As a US-based university participating in H2020, UM is an unusual asset for European consortia that need a credible North American academic partner — whether for transatlantic data comparison, access to US patient cohorts, or regulatory pathway expertise. Their combination of stem cell biology and clinical care implementation across two different health domains makes them a versatile contributor rather than a single-track specialist. For consortia applying to Horizon Europe calls that require international dimension or US clinical benchmarking, UM offers genuine differentiation.

Highlights from their portfolio

• iPSpine
  UM's only funded H2020 project (EUR 250,175), placing them in a cutting-edge RIA consortium on iPSC-based therapy for spinal disc degeneration — a high-TRL ambition in an area with significant unmet clinical need.
• RISEinFAMILY
  An MSCA-RISE project implementing family-centered care in NICUs internationally, where UM's third-party role signals their neonatal clinical research reputation extends to European implementation networks.